Company intelligence / Profile preview
BioVersys AG
Basel, Basel-Stadt, Switzerlandbioversys.com ↗
- Ownership
- Public · BIOV
- Development stage
- Other
01
Overview
BioVersys has advanced its lead asset BV100 into Phase 2 clinical trials targeting carbapenem-resistant Acinetobacter baumannii. Alpibectir for tuberculosis is in Phase 2a trials through a partnership with GSK and the University of Lille. The company’s pipeline includes additional preclinical assets targeting S. aureus and NTM infections. Its platforms focus on overcoming antimicrobial resistance via novel mechanisms of action.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
GlaxoSmithKline (GSK) – co-development of alpibectir for tuberculosis with University of Lille consortiumGIBF – strategic investment and support for China clinical expansion of BV100
Beyond the preview
Go deeper on BioVersys AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioVersys AG.